 At Week 4, subjects were to be randomized 1:1 to 1 of 2 DB maintenance treatment groups Low-Dose or High-Dose, stratified by Week 4 clinical responder status clinical response was defined as decrease in PCDAI of 15 points from the Baseline score, body weight at Week 4 and prior exposure to infliximab. Subjects randomized to the High-Dose treatment group were to receive either 40 mg adalimumab subcutaneous SC every other week eow if Week 4 body weight 40 kg or 20 mg adalimumab SC eow if Week 4 body weight 40 kg. Subjects randomized to the Low-Dose treatment group were to receive either 20 mg adalimumab SC eow if Week 4 body weight 40 kg or 10 mg adalimumab SC eow if Week 4 body weight 40 kg. 